Baxter International Inc.

09.12.2004 – 14:06
Baxter Suspends Enrollment in European Clinical Trial for PreFluCel
Deerfield, Illinois (ots/PRNewswire) - Baxter International Inc. (NYSE: BAX) announced today that it has voluntarily suspended enrollment in the Phase II/III clinical study currently underway in Europe of its PreFluCel influenza vaccine, due to a higher than expected rate of mild fever and associated symptoms in the clinical trial participants. "In developing a ...
plus
29.07.2004 – 14:09
Baxter and Cerus Enter Agreement with Asian Partner for Commercialization of Intercept Blood System for Platelets - Agreement to Help Address the Need for a Safer Blood Supply in Asia
DEERFIELD, Ill., and CONCORD, Calif. (ots) - Subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for platelets in parts of Asia. The ...
plus